



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

May 2016





HIV/AIDS Drug Treatment Program

Monthly Report

© 2016 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
608 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8202
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.cfenet.ubc.ca
Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA
CENTRE for EXCELLENCE
in HIV/AIDS



This document is best viewed in colour.
Drug definitions available in the back.



EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

May 2016

N = 7060



Health Authority	Male	Female	All
FRASER	1322	385	1707
INTERIOR	367	99	466
NORTHERN	124	75	199
VANCOUVER COASTAL	3377	451	3828
VANCOUVER ISLAND	670	150	820
	5860	1160	7020
		Unknown/not stated:	40
		Total:	7060

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (May 2011 - May 2016)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (May 2011 - May 2016)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (May 2011 - May 2016)






1.5 BC-CfE Enrollment: New Antiretroviral Participants (May 2011 - May 2016)






1.6 Percent Distribution of Active Participants by CD4 Count (May 2011 - May 2016)






1.7 Percent Distribution of Inactive Participants by CD4 Count (May 2011 - May 2016)





1.8 Active and Inactive Participants (May 2011 - May 2016)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (May 2011 - May 2016)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (May 2011 - May 2016)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(May 2011 - May 2016)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (May 2011 - May 2016)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(May 2011 - May 2016)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (May 2011 - May 2016)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(May 2011 - May 2016)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (May 2011 - May 2016)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(May 2011 - May 2016)






1.18 Baseline CD4 for Antiretroviral First Starts (May 2011 - May 2016)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
(May 2011 - May 2016)**






1.20 Cumulative Resistance Testing Results by Resistance Category (May 2011 - May 2016)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (May 2011 - May 2016)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2016
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	24	5	0	5	5	810	5	<40	3
1988	24	7	0	7	7	510	7	<40	3
1989	23	57	2	59	52	490	57	<40	3
1990	22	61	1	62	57	510	62	<40	3
1991	22	38	3	41	32	535	38	<40	3
1992	22	70	6	76	56	550	75	<40	3
1993	21	143	16	159	143	550	157	<40	3
1994	20	97	14	111	91	570	107	<40	3
1995	19	129	26	155	120	530	145	<40	3
1996	17	373	58	431	372	600	422	<40	3
1997	16	312	38	350	309	610	341	<40	3
1998	15	219	48	267	217	570	253	<40	3
1999	15	184	42	226	184	530	214	<40	3
2000	15	138	38	176	146	565	171	<40	3
2001	14	134	34	168	138	580	159	<40	3
2002	13	143	29	172	137	600	161	<40	3
2003	13	172	33	205	171	600	194	<40	3
2004	12	178	41	219	185	570	205	<40	3
2005	11	209	49	258	219	580	250	<40	3
2006	10	217	42	259	207	590	239	<40	3
2007	9	280	55	335	276	590	321	<40	3
2008	8	317	71	388	321	620	368	<40	3
2009	7	352	76	428	359	650	411	<40	3
2010	6	310	72	382	322	630	365	<40	3
2011	5	364	84	448	373	660	421	<40	3
2012	4	303	68	371	308	685	362	<40	3
2013	3	299	72	371	300	620	362	<40	3
2014	2	317	60	377	299	680	363	<40	3
2015	1	348	57	405	330	600	393	<40	3
2016	0	111	26	137	128	535	131	<40	3
Total:		5887	1161	7048					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2015	6739	760	2430	<40	2114	580
FEB-2015	6787	754	1976	<40	1730	570
MAR-2015	6834	748	2173	<40	1899	570
APR-2015	6845	739	2150	<40	1908	580
MAY-2015	6882	740	2032	<40	1788	560
JUN-2015	6898	740	2254	<40	1962	580
JUL-2015	6925	739	2037	<40	1797	580
AUG-2015	6922	752	2075	<40	1774	580
SEP-2015	6923	749	2265	<40	1972	580
OCT-2015	6957	740	2100	<40	1801	590
NOV-2015	7009	722	2064	<40	1800	580
DEC-2015	6991	725	2015	<40	1769	600
JAN-2016	6978	735	2264	<40	1926	590
FEB-2016	6997	735	2067	<40	1775	590
MAR-2016	7008	736	2158	<40	1826	600
APR-2016	7029	733	2054	<40	1721	590
MAY-2016	7060	745	2076	<40	1412	600

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2015	1513	2042	104	1325	86	315
FEB-2015	1497	2111	103	75	87	380
MAR-2015	1469	2260	101	56	92	405
APR-2015	1475	2244	83	2239	68	465
MAY-2015	1459	2353	73	148	60	430
JUN-2015	1476	2271	96	106	89	430
JUL-2015	1469	2336	71	598	56	380
AUG-2015	1480	2303	82	2341	73	440
SEP-2015	1504	2231	91	128	79	349
OCT-2015	1486	2347	81	<40	66	405
NOV-2015	1462	2458	85	169	72	425
DEC-2015	1498	2318	79	344	61	330
JAN-2016	1509	2304	114	<40	89	460
FEB-2016	1501	2366	79	353	65	350
MAR-2016	1503	2344	84	102	77	450
APR-2016	1506	2345	86	<50	63	360
MAY-2016	1490	2417	73	<40	43	290

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2015	6706	1513	13	24	149	188	-35	11954
FEB-2015	6756	1497	7	36	187	163	50	12006
MAR-2015	6809	1469	7	29	177	144	53	12046
APR-2015	6808	1475	15	28	168	172	-1	12082
MAY-2015	6847	1459	9	33	171	150	39	12123
JUN-2015	6870	1476	5	36	153	159	23	12170
JUL-2015	6906	1469	5	25	167	149	36	12208
AUG-2015	6903	1480	7	19	145	157	-3	12238
SEP-2015	6899	1504	9	32	157	180	-4	12279
OCT-2015	6927	1486	14	24	171	147	28	12316
NOV-2015	6979	1462	9	29	183	149	52	12357
DEC-2015	6959	1498	11	22	153	181	-20	12390
JAN-2016	6951	1509	9	16	154	167	-8	12411
FEB-2016	6973	1501	5	18	177	162	22	12439
MAR-2016	6989	1503	8	25	171	170	16	12473
APR-2016	7014	1506	6	21	168	157	25	12508
MAY-2016	7048	1490	7	24	161	144	34	12539

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2015	48	6180	440	74	6742	0.71%	91.66%	6.53%	1.10%	100.00%
FEB-2015	49	6219	451	73	6792	0.72%	91.56%	6.64%	1.07%	100.00%
MAR-2015	47	6287	436	67	6837	0.69%	91.96%	6.38%	0.98%	100.00%
APR-2015	47	6296	435	67	6845	0.69%	91.98%	6.36%	0.98%	100.00%
MAY-2015	49	6334	431	68	6882	0.71%	92.04%	6.26%	0.99%	100.00%
JUN-2015	51	6329	446	72	6898	0.74%	91.75%	6.47%	1.04%	100.00%
JUL-2015	46	6359	453	67	6925	0.66%	91.83%	6.54%	0.97%	100.00%
AUG-2015	48	6360	444	70	6922	0.69%	91.88%	6.41%	1.01%	100.00%
SEP-2015	48	6372	439	64	6923	0.69%	92.04%	6.34%	0.92%	100.00%
OCT-2015	52	6399	442	64	6957	0.75%	91.98%	6.35%	0.92%	100.00%
NOV-2015	55	6442	445	67	7009	0.78%	91.91%	6.35%	0.96%	100.00%
DEC-2015	52	6429	448	62	6991	0.74%	91.96%	6.41%	0.89%	100.00%
JAN-2016	54	6415	448	61	6978	0.77%	91.93%	6.42%	0.87%	100.00%
FEB-2016	54	6447	437	59	6997	0.77%	92.14%	6.25%	0.84%	100.00%
MAR-2016	53	6456	438	61	7008	0.76%	92.12%	6.25%	0.87%	100.00%
APR-2016	53	6477	442	57	7029	0.75%	92.15%	6.29%	0.81%	100.00%
MAY-2016	56	6510	439	55	7060	0.79%	92.21%	6.22%	0.78%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		stavudine		didanosine		emtricitabine		tenofovir <TAF>	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2015	10 29%	2583 40%	10 29%	2220 34%	0 0%	127 2%	0 0%	19 0%	0 0%	11 0%	25 71%	3846 59%	0 0%	0 0%
FEB-2015	8 15%	2593 39%	8 15%	2228 34%	0 0%	127 2%	0 0%	19 0%	0 0%	9 0%	44 85%	3878 59%	0 0%	0 0%
MAR-2015	10 25%	2610 39%	10 25%	2253 34%	0 0%	124 2%	0 0%	18 0%	0 0%	10 0%	30 75%	3913 59%	0 0%	0 0%
APR-2015	10 29%	2626 40%	10 29%	2267 34%	0 0%	117 2%	0 0%	16 0%	0 0%	9 0%	24 69%	3911 59%	0 0%	0 0%
MAY-2015	8 20%	2638 40%	7 18%	2280 34%	0 0%	118 2%	0 0%	14 0%	0 0%	9 0%	32 80%	3923 59%	0 0%	0 0%
JUN-2015	10 21%	2633 39%	10 21%	2287 34%	0 0%	115 2%	0 0%	15 0%	0 0%	9 0%	37 79%	3942 59%	0 0%	0 0%
JUL-2015	4 11%	2659 40%	4 11%	2313 34%	0 0%	111 2%	0 0%	14 0%	0 0%	9 0%	34 89%	3945 59%	0 0%	0 0%
AUG-2015	12 40%	2675 40%	11 37%	2334 35%	1 3%	111 2%	0 0%	12 0%	0 0%	9 0%	18 60%	3941 59%	0 0%	0 0%
SEP-2015	17 41%	2715 40%	15 37%	2373 35%	0 0%	107 2%	1 2%	13 0%	0 0%	6 0%	24 59%	3911 58%	0 0%	0 0%
OCT-2015	11 30%	2747 41%	10 27%	2404 36%	0 0%	102 2%	0 0%	13 0%	0 0%	8 0%	26 70%	3901 58%	0 0%	0 0%
NOV-2015	17 41%	2787 41%	15 37%	2442 36%	1 2%	102 2%	0 0%	13 0%	0 0%	8 0%	24 59%	3911 58%	0 0%	0 0%
DEC-2015	5 15%	2795 41%	5 15%	2456 36%	0 0%	95 1%	0 0%	12 0%	0 0%	8 0%	28 85%	3886 57%	0 0%	0 0%
JAN-2016	4 19%	2821 42%	4 19%	2488 37%	0 0%	93 1%	0 0%	11 0%	0 0%	8 0%	17 81%	3856 57%	0 0%	0 0%
FEB-2016	10 36%	2855 42%	9 32%	2523 37%	1 4%	94 1%	0 0%	11 0%	0 0%	8 0%	18 64%	3835 57%	0 0%	0 0%
MAR-2016	9 26%	2881 42%	7 21%	2546 38%	1 3%	94 1%	0 0%	11 0%	0 0%	8 0%	25 74%	3818 56%	0 0%	0 0%
APR-2016	12 34%	2898 43%	9 26%	2572 38%	3 9%	93 1%	0 0%	11 0%	0 0%	8 0%	23 66%	3823 56%	0 0%	5 0%
MAY-2016	8 26%	2902 43%	8 26%	2586 38%	0 0%	92 1%	0 0%	11 0%	0 0%	7 0%	23 74%	3844 56%	0 0%	6 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)

	tenofovir <TDF>			
	Initial		All	
JAN-2015	25	71%	4210	64%
FEB-2015	44	85%	4241	64%
MAR-2015	30	75%	4269	64%
APR-2015	24	69%	4267	64%
MAY-2015	33	83%	4277	64%
JUN-2015	37	79%	4293	64%
JUL-2015	34	89%	4295	64%
AUG-2015	18	60%	4281	64%
SEP-2015	24	59%	4251	63%
OCT-2015	27	73%	4239	63%
NOV-2015	25	61%	4243	63%
DEC-2015	28	85%	4211	62%
JAN-2016	17	81%	4173	62%
FEB-2016	18	64%	4142	61%
MAR-2016	26	76%	4121	61%
APR-2016	23	66%	4115	61%
MAY-2016	23	74%	4130	61%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	(fos)amprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2015	0 0%	12 0%	6 50%	2029 60%	6 50%	930 28%	0 0%	383 11%	0 0%	4 0%	0 0%	1 0%	0 0%	18 1%
FEB-2015	0 0%	10 0%	8 31%	2029 60%	18 69%	960 28%	0 0%	380 11%	0 0%	5 0%	0 0%	1 0%	0 0%	17 1%
MAR-2015	0 0%	11 0%	8 47%	2044 60%	8 47%	970 29%	0 0%	375 11%	1 6%	6 0%	0 0%	1 0%	0 0%	17 1%
APR-2015	0 0%	12 0%	7 33%	2025 60%	14 67%	988 29%	0 0%	364 11%	0 0%	6 0%	0 0%	1 0%	0 0%	18 1%
MAY-2015	0 0%	12 0%	10 63%	2000 59%	6 38%	1018 30%	0 0%	360 11%	0 0%	4 0%	0 0%	1 0%	0 0%	19 1%
JUN-2015	0 0%	11 0%	8 44%	1966 58%	10 56%	1037 31%	0 0%	358 11%	0 0%	5 0%	0 0%	1 0%	0 0%	18 1%
JUL-2015	0 0%	10 0%	1 7%	1958 58%	11 79%	1050 31%	1 7%	351 10%	0 0%	5 0%	0 0%	1 0%	1 7%	19 1%
AUG-2015	0 0%	11 0%	1 9%	1946 58%	7 64%	1054 31%	3 27%	345 10%	0 0%	4 0%	0 0%	1 0%	0 0%	18 1%
SEP-2015	0 0%	11 0%	4 25%	1912 58%	11 69%	1061 32%	1 6%	338 10%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
OCT-2015	0 0%	10 0%	5 31%	1900 57%	10 63%	1087 33%	1 6%	331 10%	0 0%	4 0%	0 0%	1 0%	0 0%	17 1%
NOV-2015	0 0%	10 0%	5 31%	1876 56%	9 56%	1107 33%	2 13%	329 10%	0 0%	4 0%	0 0%	1 0%	0 0%	17 1%
DEC-2015	0 0%	11 0%	3 25%	1839 56%	8 67%	1119 34%	1 8%	328 10%	0 0%	4 0%	0 0%	1 0%	0 0%	17 1%
JAN-2016	0 0%	11 0%	5 45%	1823 55%	5 45%	1131 34%	1 9%	327 10%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
FEB-2016	0 0%	10 0%	6 46%	1794 55%	6 46%	1160 35%	1 8%	318 10%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
MAR-2016	0 0%	9 0%	4 25%	1773 55%	11 69%	1175 36%	1 6%	300 9%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
APR-2016	0 0%	9 0%	1 7%	1749 54%	14 93%	1206 37%	0 0%	294 9%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
MAY-2016	0 0%	8 0%	2 17%	1733 53%	10 83%	1224 38%	0 0%	283 9%	0 0%	2 0%	0 0%	1 0%	0 0%	16 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	tipranavir			
	Initial		All	
JAN-2015	0	0%	1	0%
FEB-2015	0	0%	1	0%
MAR-2015	0	0%	1	0%
APR-2015	0	0%	1	0%
MAY-2015	0	0%	1	0%
JUN-2015	0	0%	1	0%
JUL-2015	0	0%	1	0%
AUG-2015	0	0%	1	0%
SEP-2015	0	0%	1	0%
OCT-2015	0	0%	1	0%
NOV-2015	0	0%	1	0%
DEC-2015	0	0%	1	0%
JAN-2016	0	0%	1	0%
FEB-2016	0	0%	1	0%
MAR-2016	0	0%	1	0%
APR-2016	0	0%	1	0%
MAY-2016	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2015	6 75%	1174 45%	0 0%	306 12%	0 0%	900 34%	2 25%	253 10%
FEB-2015	4 50%	1169 45%	0 0%	306 12%	0 0%	892 34%	4 50%	250 10%
MAR-2015	7 88%	1167 45%	0 0%	303 12%	0 0%	889 34%	1 13%	255 10%
APR-2015	4 67%	1148 44%	1 17%	305 12%	0 0%	888 34%	1 17%	259 10%
MAY-2015	7 58%	1139 44%	1 8%	309 12%	0 0%	887 34%	4 33%	260 10%
JUN-2015	2 29%	1133 44%	0 0%	317 12%	0 0%	877 34%	5 71%	262 10%
JUL-2015	8 89%	1122 44%	0 0%	311 12%	0 0%	880 34%	1 11%	260 10%
AUG-2015	4 80%	1104 43%	0 0%	307 12%	0 0%	879 35%	1 20%	253 10%
SEP-2015	8 89%	1097 43%	1 11%	305 12%	0 0%	873 35%	0 0%	256 10%
OCT-2015	2 50%	1083 43%	0 0%	312 12%	1 25%	867 35%	1 25%	251 10%
NOV-2015	4 67%	1074 43%	0 0%	312 12%	0 0%	865 35%	2 33%	254 10%
DEC-2015	3 100%	1057 43%	0 0%	312 13%	0 0%	863 35%	0 0%	254 10%
JAN-2016	2 100%	1035 42%	0 0%	302 12%	0 0%	855 35%	0 0%	256 10%
FEB-2016	3 60%	1008 41%	0 0%	306 13%	1 20%	857 35%	1 20%	260 11%
MAR-2016	2 50%	997 41%	0 0%	307 13%	1 25%	854 35%	1 25%	260 11%
APR-2016	3 33%	991 41%	1 11%	308 13%	3 33%	845 35%	2 22%	261 11%
MAY-2016	5 63%	986 41%	0 0%	303 13%	0 0%	835 35%	3 38%	262 11%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	dolutegravir		elvitegravir		maraviroc		raltegravir		enfuvirtide	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2015	13 72%	540 30%	4 22%	348 19%	1 6%	68 4%	1 6%	879 49%	0 0%	1 0%
FEB-2015	14 58%	575 31%	8 33%	354 19%	0 0%	73 4%	2 8%	879 48%	0 0%	1 0%
MAR-2015	9 50%	599 32%	5 28%	367 20%	0 0%	69 4%	4 22%	868 47%	0 0%	2 0%
APR-2015	7 50%	627 33%	4 29%	373 20%	2 14%	67 4%	1 7%	861 45%	0 0%	2 0%
MAY-2015	11 65%	665 34%	4 24%	380 20%	1 6%	70 4%	2 12%	863 44%	0 0%	2 0%
JUN-2015	15 56%	710 35%	8 30%	394 20%	0 0%	72 4%	4 15%	875 44%	0 0%	1 0%
JUL-2015	11 58%	746 36%	4 21%	404 20%	0 0%	71 3%	4 21%	866 42%	0 0%	1 0%
AUG-2015	11 69%	782 38%	4 25%	413 20%	0 0%	70 3%	1 6%	854 41%	0 0%	1 0%
SEP-2015	17 85%	849 40%	1 5%	412 19%	0 0%	65 3%	2 10%	855 40%	0 0%	1 0%
OCT-2015	14 70%	889 40%	6 30%	435 20%	0 0%	65 3%	0 0%	851 39%	0 0%	1 0%
NOV-2015	15 71%	938 42%	6 29%	438 19%	0 0%	67 3%	0 0%	854 38%	0 0%	1 0%
DEC-2015	11 50%	988 43%	10 45%	445 19%	0 0%	66 3%	1 5%	841 37%	0 0%	1 0%
JAN-2016	6 55%	1021 44%	4 36%	461 20%	0 0%	67 3%	1 9%	822 35%	0 0%	1 0%
FEB-2016	7 64%	1063 45%	4 36%	470 20%	0 0%	61 3%	0 0%	813 34%	0 0%	1 0%
MAR-2016	15 79%	1117 46%	2 11%	484 20%	0 0%	60 2%	2 11%	806 33%	0 0%	1 0%
APR-2016	12 67%	1157 47%	4 22%	494 20%	0 0%	60 2%	2 11%	799 32%	0 0%	1 0%
MAY-2016	13 76%	1187 47%	4 24%	496 20%	0 0%	60 2%	0 0%	799 32%	0 0%	1 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2015	2347	34.81	2123	31.49	1137	16.86	179	2.65	74	1.10	882	13.08
FEB-2015	2363	34.79	2110	31.07	1176	17.31	178	2.62	73	1.07	892	13.13
MAR-2015	2398	35.07	2112	30.89	1203	17.60	184	2.69	67	0.98	873	12.77
APR-2015	2388	34.89	2095	30.61	1237	18.07	184	2.69	67	0.98	874	12.77
MAY-2015	2392	34.76	2094	30.43	1274	18.51	179	2.60	68	0.99	875	12.71
JUN-2015	2363	34.26	2078	30.12	1321	19.15	172	2.49	72	1.04	892	12.93
JUL-2015	2370	34.22	2068	29.86	1352	19.52	171	2.47	67	0.97	897	12.95
AUG-2015	2365	34.17	2044	29.53	1382	19.97	168	2.43	70	1.01	893	12.90
SEP-2015	2323	33.55	2032	29.35	1446	20.89	168	2.43	64	0.92	890	12.86
OCT-2015	2325	33.42	2005	28.82	1491	21.43	167	2.40	64	0.92	905	13.01
NOV-2015	2318	33.07	2012	28.71	1540	21.97	160	2.28	67	0.96	912	13.01
DEC-2015	2291	32.77	1983	28.37	1580	22.60	161	2.30	62	0.89	914	13.07
JAN-2016	2289	32.80	1946	27.89	1612	23.10	158	2.26	61	0.87	912	13.07
FEB-2016	2286	32.67	1926	27.53	1670	23.87	153	2.19	59	0.84	903	12.91
MAR-2016	2271	32.41	1907	27.21	1710	24.40	155	2.21	61	0.87	904	12.90
APR-2016	2251	32.02	1896	26.97	1760	25.04	154	2.19	57	0.81	911	12.96
MAY-2016	2264	32.07	1889	26.76	1787	25.31	156	2.21	55	0.78	909	12.88

Definitions:

n is number of participants on the specified regimen class in the specified month
 % is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2015	24	2	2	8	3	9	370
FEB-2015	36	3	3	9	3	16	469
MAR-2015	29	2	5	5	8	7	386
APR-2015	28	8	3	4	3	10	335
MAY-2015	33	4	6	9	5	8	290
JUN-2015	36	6	2	8	8	11	370
JUL-2015	25	6	2	2	6	7	380
AUG-2015	19	2	3	4	2	7	400
SEP-2015	32	7	1	5	2	15	505
OCT-2015	24	4	2	3	4	9	450
NOV-2015	29	5	1	5	6	10	400
DEC-2015	22	2	3	4	5	7	370
JAN-2016	16	2	3	0	5	3	380
FEB-2016	18	4	0	6	3	5	331
MAR-2016	25	4	3	4	7	6	365
APR-2016	21	2	1	2	2	10	600
MAY-2016	24	2	1	3	4	14	514

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2015	10390	2658
FEB-2015	10436	2665
MAR-2015	10475	2674
APR-2015	10495	2686
MAY-2015	10549	2710
JUN-2015	10635	2757
JUL-2015	10704	2805
AUG-2015	10770	2861
SEP-2015	10855	2916
OCT-2015	10907	2956
NOV-2015	10970	2996
DEC-2015	11016	3023
JAN-2016	11051	3054
FEB-2016	11145	3136
MAR-2016	11206	3184
APR-2016	11252	3217
MAY-2016	11316	3269

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved

Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
May 2016

N = 7060

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

May 2016

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

May 2016

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

May 2016

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

May 2016

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

May 2016

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





**4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
INTERIOR Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	33	46	21
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	71	92	53	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	325	429	248	
THOMPSON/CARIBOO/ SHUSWAP	0-19	5	5	0
	20-34	22	22	15
	35-49	57	65	47
	50+	97	143	82
Total HSDA:	181	235	144	
Total HA:		610	802	466

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	9	9	*
	20-34	55	56	*
	35-49	173	203	*
	50+	373	534	*
Total HA:		610	802	466

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	475	636	367
Female	135	166	99

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	466	53	540	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	17	10
	5 years or more	6	5
	<5 years	10	6
	Total HSDA:	33	21
KOOTENAY BOUNDARY	10 years or more	35	24
	5 years or more	21	18
	<5 years	15	11
	Total HSDA:	71	53
OKANAGAN	10 years or more	170	121
	5 years or more	75	60
	<5 years	80	67
	Total HSDA:	325	248
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	92	65
	5 years or more	39	36
	<5 years	50	43
	Total HSDA:	181	144
Total HA:		610	466

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	314	220
	5 years or more	141	119
	<5 years	155	127
Total HA:		610	466

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	36	51	13	22
KOOTENAY BOUNDARY	63	111	26	43
OKANAGAN	196	677	63	246
THOMPSON/CARIBOO/SHUSWAP	126	417	43	110
Total:	421	1256	145	421

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	0
KOOTENAY BOUNDARY	12
OKANAGAN	39
THOMPSON/CARIBOO/SHUSWAP	39
Total:	90

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	6
	20-34	30	31	26
	35-49	110	119	80
	50+	175	237	144
	Total HSDA:	322	394	256
FRASER NORTH	0-19	19	19	*
	20-34	106	107	*
	35-49	352	400	*
	50+	463	727	*
	Total HSDA:	940	1253	733
FRASER SOUTH	0-19	10	10	7
	20-34	102	104	74
	35-49	354	406	288
	50+	423	628	349
	Total HSDA:	889	1148	718
Total HA:		2151	2795	1707

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	36	36	17
	20-34	238	242	188
	35-49	816	925	624
	50+	1061	1592	878
Total HA:		2151	2795	1707

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1626	2144	1322
Female	525	651	385

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1707	50	610	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	153	114
	5 years or more	88	73
	<5 years	81	69
	Total HSDA:	322	256
FRASER NORTH	10 years or more	454	332
	5 years or more	243	200
	<5 years	243	201
	Total HSDA:	940	733
FRASER SOUTH	10 years or more	407	312
	5 years or more	244	203
	<5 years	238	203
	Total HSDA:	889	718
Total HA:		2151	1707

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1014	758
	5 years or more	575	476
	<5 years	562	473
Total HA:		2151	1707

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	127	405	40	76
FRASER NORTH	228	1409	61	256
FRASER SOUTH	200	1177	43	324
Total:	555	2991	144	656

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	182
FRASER NORTH	614
FRASER SOUTH	496
Total:	1292

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	0
	20-34	*	*	18
	35-49	*	*	75
	50+	*	*	176
	Total HSDA:		310	445
RICHMOND	0-19	5	5	*
	20-34	25	26	*
	35-49	46	49	*
	50+	78	117	*
	Total HSDA:		154	197
VANCOUVER	0-19	54	57	7
	20-34	394	400	313
	35-49	1570	1816	1171
	50+	2447	4075	1944
	Total HSDA:		4465	6348
Total HA:		4929	6990	3828

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	61	64	8
	20-34	438	445	352
	35-49	1705	1968	1285
	50+	2725	4513	2183
Total HA:		4929	6990	3828

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
	2	2	0
Male	4333	6147	3377
Female	594	841	451

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3828	51	610	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	172	143
	5 years or more	56	53
	<5 years	82	73
	Total HSDA:	310	269
RICHMOND	10 years or more	70	52
	5 years or more	40	32
	<5 years	44	40
	Total HSDA:	154	124
VANCOUVER	10 years or more	2279	1653
	5 years or more	1145	897
	<5 years	1041	885
	Never on ART	0	0
	Total HSDA:	4465	3435
Total HA:	4929	3828	

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	2521	1848
	5 years or more	1241	982
	<5 years	1167	998
	Never on ART	0	0
Total HA:		4929	3828

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	141	368	52	91
RICHMOND	42	261	14	89
VANCOUVER	538	9867	205	5258
Total:	721	10496	271	5438

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	95

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		277	388
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		106	140
SOUTH VANCOUVER ISLAND	0-19	8	8	*
	20-34	48	50	*
	35-49	208	244	*
	50+	393	615	*
	Total HSDA:		657	917
Total HA:		1040	1445	820

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	12	12	*
	20-34	82	87	*
	35-49	326	378	*
	50+	620	968	*
Total HA:		1040	1445	820

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	839	1168	670
Female	201	277	150

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	820	52	480	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	133	105
	5 years or more	64	56
	<5 years	80	64
	Total HSDA:	277	225
NORTH VANCOUVER ISLAND	10 years or more	48	37
	5 years or more	28	22
	<5 years	30	24
	Total HSDA:	106	83
SOUTH VANCOUVER ISLAND	10 years or more	327	236
	5 years or more	171	139
	<5 years	159	137
	Total HSDA:	657	512
Total HA:		1040	820

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	508	378
5 years or more	263	217
<5 years	269	225
Total HA:	1040	820

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	172	733	82	194
NORTH VANCOUVER ISLAND	117	235	46	67
SOUTH VANCOUVER ISLAND	182	1538	48	512
Total:	471	2506	176	773

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	49
NORTH VANCOUVER ISLAND	28
SOUTH VANCOUVER ISLAND	90
Total:	167

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.13 Distribution of Participants in BC-CfE Registries by Age and Gender NORTHERN Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		38	46
NORTH WEST	0-19	*	*	0
	20-34	*	*	5
	35-49	*	*	19
	50+	*	*	21
	Total HSDA:		63	95
NORTHERN INTERIOR	0-19	7	7	*
	20-34	28	30	*
	35-49	74	92	*
	50+	74	121	*
	Total HSDA:		183	250
Total HA:		284	391	199

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	9	9	*
	20-34	38	45	*
	35-49	112	144	*
	50+	125	193	*
Total HA:		284	391	199

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	176	245	124
Female	108	146	75

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	199	49	530	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	13	6
	5 years or more	15	8
	<5 years	10	8
	Total HSDA:	38	22
NORTH WEST	10 years or more	16	8
	5 years or more	27	21
	<5 years	20	16
	Total HSDA:	63	45
NORTHERN INTERIOR	10 years or more	55	35
	5 years or more	52	39
	<5 years	76	58
	Total HSDA:	183	132
Total HA:		284	199

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	84	49
5 years or more	94	68
<5 years	106	82
Total HA:	284	199

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	32	58	9	11
NORTH WEST	63	141	17	25
NORTHERN INTERIOR	101	394	25	178
Total:	196	593	51	214

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	6
NORTH WEST	15
NORTHERN INTERIOR	20
Total:	41

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	*	10	*
	KOOTENAY BOUNDARY	*	6	*
	OKANAGAN	*	29	*
	THOMPSON/CARIBOO/SHUSWAP	*	38	*
	Total HA:	47	83	34
FRASER	FRASER EAST	30	38	25
	FRASER NORTH	58	89	45
	FRASER SOUTH	73	100	60
	Total HA:	161	227	130
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBADI	22	42	19
	RICHMOND	7	12	6
	VANCOUVER	506	788	427
	Total HA:	535	842	452
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	51	76	39
	NORTH VANCOUVER ISLAND	13	22	9
	SOUTH VANCOUVER ISLAND	35	72	27
	Total HA:	99	170	75
NORTHERN	NORTH EAST	8	10	5
	NORTH WEST	31	54	23
	NORTHERN INTERIOR	65	97	54
	Total HA:	104	161	82
Total:		946	1483	773

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	594	951	477
Female	352	532	296

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	773	49	470	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicstat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicstat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

Delavirdine (Rescriptor, DLV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from ViiV Healthcare.





Descovy (DSC): the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay, DTG): an INTEGRASE INHIBITOR from ViiV Healthcare.

Efavirenz (Sustiva, Auro efavirenz, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine (FTC): a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intence, ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya (GNV): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Indinavir (Crixivan, IDV): a PROTEASE INHIBITOR from Merck.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.





Maraviroc (Celsentri, MVC): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant, RPV): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.





Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

